Table 1.

Demographic, clinical characteristics and ¹¹C-CFT PET/CT data of all patients

	PD	MSA-P	PSP	VP	P value
Number	80	54	15	17	–
Sex(male/female)	31/49	24/30	8/7	11/6	0.229
Age(year)	62.75 ± 10.92	60.39 ± 8.57c	65.07 ± 3.94	69.29 ± 5.52	0.006*
Disease duration(year)	5.70 ± 3.22a	4.07 ± 1.78	4.93 ± 1.53	4.82 ± 1.24	0.005*
H-Y	2.13 ± 0.95b	2.31 ± 0.77b	3.17 ± 1.03	2.06 ± 0.43b	<0.001*
MDS-UPDRS-III	31.23 ± 19.24b	36.83 ± 17.95b	51.87 ± 14.35	28.24 ± 9.00b	<0.001*
MoCA	21.54 ± 4.77b	21.63 ± 4.00b	17.20 ± 3.45	21.06 ± 4.43	0.004*
11C-CFT SUVR
Caudate	1.59 ± 0.38b, c	1.51 ± 0.34c	1.26 ± 0.92c	1.82 ± 0.47	0.010*
Anterior Putamen	2.09 ± 0.45c	1.99 ± 0.39c	1.84 ± 0.76c	2.42 ± 0.73	0.018*
Posterior Putamen	1.80 ± 0.43c	1.70 ± 0.34c	1.59 ± 0.46c	2.26 ± 0.71	<0.001*
Asymmetry Index, %
Caudate	9.37 ± 7.48	6.93 ± 5.93	6.63 ± 4.67	6.01 ± 6.20	0.092
Anterior Putamen	13.86 ± 7.61a, b, c	10.71 ± 7.28	10.45 ± 7.39	9.02 ± 7.09	0.003*
Posterior Putamen	10.30 ± 8.35	8.20 ± 5.50	7.43 ± 6.59	8.13 ± 8.00	0.305

Data are given as mean ± SD. P values of ¹¹C-CFT uptake were calculated by generalized linear model, adjusting for MDS-UPDRS-III, MoCA, disease duration, age and H-Y.

PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism, H-Y Hoehn-Yahr scale, MDS-UPDRS-III Movement Disorder Society Unified Parkinson Disease Rating Scale part III, MoCA Montreal Cognitive Assessment, SUVR standardized uptake value ratio.

*P < 0.05. In post hoc, ^aP < 0.05 vs. MSA-P, ^bP < 0.05 vs. PSP, ^cP < 0.05 vs. VP.